Will Biogen Be Able to Move Past the Drama Surrounding Its Alzheimer’s Disease Drug?

Key Points The FDA approval for Biogen’s Alzheimer’s disease drug, Aduhelm, remains highly controversial. Some healthcare providers are saying they won’t prescribe Aduhelm, while some health plans are saying they won’t pay for the drug. Aduhelm should still generate tremendous sales for Biogen despite the ongoing drama. Biogen ‘s ( NASDAQ:BIIB ) history so far with Alzheimer’s disease drug Aduhelm is like a biotech soap opera.

Read the source article at News Break
2021-07-31 15:03:00